Will Xeris Biopharma (XERS) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 08/01/24
Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024Business Wire • 07/25/24
Xeris Biopharma (XERS) Now Trades Above Golden Cross: Time to Buy?Zacks Investment Research • 07/24/24
Xeris Biopharma unveils CEO succession plan, John Shannon to lead companyProactive Investors • 07/08/24
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing's Syndrome Patients at ENDO 2024Business Wire • 06/03/24
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)Business Wire • 05/30/24
Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent EventsBusiness Wire • 05/09/24
Xeris Biopharma and Beta Bionics join forces to develop dual-hormone pump for diabetesProactive Investors • 05/06/24
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta BionicsBusiness Wire • 05/06/24
Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024Business Wire • 05/02/24
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceBusiness Wire • 04/02/24
Xeris Biopharma secures $200M in capital in debt refinancing deal; sees big 4Q revenue jumpProactive Investors • 03/06/24
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent EventsBusiness Wire • 03/06/24
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin CapitalBusiness Wire • 03/06/24
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024Business Wire • 02/28/24
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science ConferenceBusiness Wire • 02/05/24